Lindor Qunaj

966 total citations · 1 hit paper
9 papers, 661 citations indexed

About

Lindor Qunaj is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Lindor Qunaj has authored 9 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 4 papers in Oncology and 2 papers in Neurology. Recurrent topics in Lindor Qunaj's work include Viral-associated cancers and disorders (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Lindor Qunaj is often cited by papers focused on Viral-associated cancers and disorders (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Lindor Qunaj collaborates with scholars based in United States and United Kingdom. Lindor Qunaj's co-authors include Lalit K. Beura, Daniel L. Barber, Kristin G. Anderson, Vaiva Vezys, Thomas S. Griffith, Heungsup Sung, David Masopust, Justin J. Taylor, Katrin D. Mayer-Barber and Britnie R. James and has published in prestigious journals such as Blood, Nature Protocols and The American Journal of Medicine.

In The Last Decade

Lindor Qunaj

9 papers receiving 656 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intravascular staining for discrimination of vascular and tissue leukocytes

2014 565 citations Kristin G. Anderson, Katrin D. Mayer-Barber et al. Nature Protocols profile →

Peers

Countries citing papers authored by Lindor Qunaj

Since Specialization

Citations

This map shows the geographic impact of Lindor Qunaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindor Qunaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindor Qunaj more than expected).

Fields of papers citing papers by Lindor Qunaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindor Qunaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindor Qunaj. The network helps show where Lindor Qunaj may publish in the future.

Co-authorship network of co-authors of Lindor Qunaj

This figure shows the co-authorship network connecting the top 25 collaborators of Lindor Qunaj. A scholar is included among the top collaborators of Lindor Qunaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindor Qunaj. Lindor Qunaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer 2023 ·Frontiers in Oncology ·Lindor Qunaj, Michael May, Alfred I. Neugut, (unknown)	17
2	Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data 2023 ·Seminars in Oncology ·(unknown), (unknown), Michael May, Lindor Qunaj, Wafaa El‐Sadr, Wendy K. Chung, Paul S. Appelbaum, Judith S. Jacobson, Jessica Justman, Alfred I. Neugut	1
3	Polycythemia Vera Presenting as ST-Segment Elevation Myocardial Infarction 2022 ·The American Journal of Medicine ·Eric Hirsch, Lindor Qunaj, Azeem Latib, Benjamin Galen	1
4	Compulsory Licensing of Pharmaceuticals in High‐Income Countries: A Comparative Analysis 2022 ·Milbank Quarterly ·Lindor Qunaj, Anna Kaltenboeck, Peter B. Bach	2
5	Delays in the Publication of Important Clinical Trial Findings in Oncology 2018 ·JAMA Oncology ·Lindor Qunaj, (unknown), Coral L. Atoria, Renee L. Gennarelli, Jennifer Miller, Peter B. Bach	23
6	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base 2017 ·Leukemia & lymphoma ·Lindor Qunaj, Jorge J. Castillo, Adam J. Olszewski	26
7	Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database 2016 ·Blood Advances ·Jaleh Fallah, Lindor Qunaj, Adam J. Olszewski	23
8	CD20-Negative Large B-Cell Lymphomas: Analysis of the National Cancer Data Base 2016 ·Blood ·Lindor Qunaj, Jorge J. Castillo, Adam J. Olszewski	3
9	Intravascular staining for discrimination of vascular and tissue leukocytes breakdown → 2014 ·Nature Protocols ·Kristin G. Anderson, Katrin D. Mayer-Barber, Heungsup Sung, Lalit K. Beura, Britnie R. James, Justin J. Taylor, Lindor Qunaj, Thomas S. Griffith, Vaiva Vezys, Daniel L. Barber, David Masopust	565

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact